Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.48 |
| ▸ | PIK3CB | P42338 | 1/20 | 0.48 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.45 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | MEN1 | O00255 | 3/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 3/20 | 0.45 |
| ▸ | AURKA | O14965 | 3/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.45 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.45 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.44 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.44 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.44 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.43 |
| ▸ | IKBKB | O14920 | 1/20 | 0.43 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.43 |
| ▸ | CHEK2 | O96017 | 1/20 | 0.43 |
| ▸ | PRKCG | P05129 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3302653 | 0.82 | LMNA (0.67) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL5443900 | 0.82 | SCN9A (0.51) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL5394104 | 0.82 | EPHB4 (0.45) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL4767203 | 0.81 | NPC1 (0.46) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL3988183 | 0.81 | AURKA (0.65) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL23887607 | 0.80 | SYK (0.42) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL19089362 | 0.80 | KDR (0.54) | AURKACDK1KDRROCK1AGPAT2 | |
| SCHEMBL4426737 | 0.80 | AURKA (0.69) | PIK3CAPIK3CBPIK3CGNPC1MAPT | |
| SCHEMBL20618595 | 0.79 | ROCK2 (0.46) | NPC1MAPTRAB9AMEN1KMT2A | |
| SCHEMBL27625434 | 0.79 | NFKB1 (0.56) | NPC1MAPTRAB9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 33 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260034127-A1 | TREATMENT OF GVHD | KADMON CORP LLC (FR) | 2026-02-05 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | WUHAN LL SCIENCE AND TECHNOLOGY DEVELOPMENT CO. LTD. (CN) | 2023-08-17 | — | — | US | disclosed |
| US-20230174519-A1 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | KADMON CORPORATION, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| US-20230174519-A1 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | KADMON CORPORATION, LLC (US) | 2023-06-08 | — | — | US | disclosed |
| EP-4155308-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | Wuhan LL Science and Technology Development Co., Ltd. (CN) | 2023-03-29 | — | — | EP | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-20220395501-A1 | TREATMENT OF GVHD | KADMON CORP LLC (US) | 2022-12-15 | — | — | US | disclosed |
| US-11311541-B2 | Treatment of GVHD | KADMON CORPORATION, LLC (US) | 2022-04-26 | — | — | US | disclosed |
| WO-2015157556-A1 | TREATMENT OF GVHD | KADMON CORPORATION, LLC (US) | 2015-10-15 | — | — | WO | disclosed |
| CN-104903312-A | RHO KINASE INHIBITORS | KADMON CORP LLC | 2015-09-09 | — | — | CN | disclosed |
| WO-2015054317-A1 | RHO KINASE INHIBITORS | KADMON CORPORATION, LLC (US) | 2015-04-16 | — | — | WO | disclosed |
| CN-100445270-C | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2008-12-24 | — | — | CN | disclosed |
| EP-1272477-B1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2007-05-09 | — | — | EP | disclosed |
| US-7153964-B2 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2006-12-26 | — | — | US | disclosed |
| US-20030149064-A1 | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-08-07 | — | — | US | disclosed |
| CN-1406231-A | Pyrimidine compounds | ASTRAZENECA AB (SE) | 2003-03-26 | — | — | CN | disclosed |
| EP-1272477-A1 | PYRIMIDINE COMPOUNDS | AstraZeneca AB (SE) | 2003-01-08 | — | — | EP | disclosed |
| WO-2001064654-A1 | PYRIMIDINE COMPOUNDS | ASTRAZENECA AB (SE) | 2001-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230257376-A1 | ROCK INHIBITOR, AND PREPARATION METHOD THEREFOR AND USE THEREOF | ROCK1, ROCK2, RHOT2 | PIK3CA 517/4885PIK3CB 733/4885PIK3CG 666/4885 |
| US-20230174519-A1 | Inhibitors of Rho Associated Coiled-Coil Containing Protein Kinase | ROCK1, ROCK2, RHOT2 | PIK3CA 1728/4885PIK3CB 1572/4885PIK3CG 1431/4885 |
| US-20260034127-A1 | TREATMENT OF GVHD | ROCK2, RHOA, MYH2 | PIK3CA 1308/4885PIK3CB 931/4885PIK3CG 634/4885 |
| US-20030149064-A1 | Pyrimidine compounds | CDK2, CCNI, CCNY | PIK3CA 160/4885PIK3CB 316/4885PIK3CG 308/4885 |
| US-20220395501-A1 | TREATMENT OF GVHD | ROCK2, ROCK1, RHOXF2 | PIK3CA 1383/4885PIK3CB 970/4885PIK3CG 811/4885 |
| US-11311541-B2 | Treatment of GVHD | ROCK2, ROCK1, RHOA | PIK3CA 1730/4885PIK3CB 1399/4885PIK3CG 1145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.